Depakote ER Shortage Update: What Patients Need to Know in 2026

If you depend on Depakote ER — whether for epilepsy, bipolar disorder, or migraine prevention — you have probably noticed it getting harder to find at your local pharmacy. The situation has been ongoing since at least 2023 and continues into 2026. This article gives you the latest information on what is happening with Depakote ER supply, who is most affected, and what you can do right now.

What Is the Current Status of Depakote ER in 2026?

Brand-name Depakote ER 500 mg tablets have faced documented manufacturing delays from AbbVie, the brand's manufacturer, since at least mid-2023. AbbVie confirmed directly to patients in April 2024 that a manufacturing delay was "causing a supply disruption to pharmacies and wholesalers."

As of 2026, the situation for generic divalproex sodium ER has been more stable — multiple manufacturers produce generic versions and availability at most pharmacies is generally better than for the brand-name product. However, individual pharmacies may be out of stock depending on their ordering patterns and local demand.

The most affected patients are those who:

Specifically require brand-name Depakote ER because of breakthrough symptoms on generics

Take 500 mg tablets (the specific strength with documented manufacturing delays)

Live in areas where pharmacies do not routinely stock the brand-name version

What Is Causing the Depakote ER Shortage?

The Depakote ER shortage has several contributing causes:

Manufacturing delays at AbbVie. The manufacturer has acknowledged production-level disruptions specifically affecting the 500 mg ER tablet. These appear to originate at the manufacturing facility rather than in the supply chain.

Market shift to generics. As most prescriptions have shifted to generic divalproex ER, pharmacy stocking of the brand-name product has decreased significantly, amplifying any supply disruption.

Limited reporting. Unlike higher-profile shortages such as Adderall, the Depakote ER shortage has received relatively little media coverage, meaning patients may not realize the shortage is widespread and not just a local pharmacy issue.

Why Brand-Name vs. Generic Matters for Some Patients

For many patients — especially those taking Depakote ER for bipolar disorder or migraine prevention — switching to a generic is clinically straightforward and the most practical solution. Generics contain the same active ingredient and must meet FDA bioequivalence standards.

However, for patients with epilepsy who have achieved stable seizure control on brand-name Depakote ER, even small variations in drug absorption can mean the difference between staying seizure-free and having a breakthrough seizure. This is a well-recognized clinical concern with anticonvulsant medications, and many neurologists specifically write "brand medically necessary" for these patients.

Is the Shortage Getting Better or Worse?

There is no confirmed end date or resolution timeline from AbbVie for the brand-name supply issue. Unlike the ADHD stimulant shortage (which was addressed in part by DEA quota increases in 2025), Depakote ER is not a controlled substance, so there are no regulatory quota constraints to address. The problem is fundamentally a manufacturing capacity and prioritization issue at AbbVie.

Generic availability has remained relatively stable, so patients who can use generics have fared better. The shortage is specifically acute for brand-brand-specific patients.

What Can Patients Do Right Now?

Here are the most effective steps patients can take:

Start refill searches early. Begin looking 7-10 days before you run out. Depakote ER is not a controlled substance, so there are no restrictions on early refill searches.

Use medfinder. medfinder calls pharmacies near you to check which ones have your medication in stock and texts you the results.

Contact AbbVie directly. You can reach AbbVie's customer service at 1-800-633-9110 to ask about current availability and whether they can direct you to pharmacies with stock.

Report to the FDA. Patients can report drug shortages at 1-800-FDA-1088 or fda.gov/medwatch. More patient reports increase the pressure on manufacturers to address the problem.

Talk to your doctor. Do not wait until you are out of medication. Your prescriber can work with you on a plan — whether that is finding the brand, bridging with two 250 mg tablets, or carefully evaluating a formulation change.

Important Warning: Never Stop Depakote ER Abruptly

This cannot be stressed enough: stopping Depakote ER suddenly can trigger severe seizures, including potentially life-threatening status epilepticus. If you are at risk of running out, call your doctor before your supply ends — not after. Your prescriber can authorize an emergency supply or bridge prescription to keep you covered while you search for your regular medication.

The Bottom Line

The Depakote ER shortage — particularly for the brand-name 500 mg tablet — is a real, ongoing problem for many patients in 2026. While no resolution timeline exists, you are not powerless. Start early, use every available tool, and work closely with your care team. For a complete step-by-step guide, see our article on how to find Depakote ER in stock near you.